AZ6197
CAS No. 2023003-94-1
AZ6197 ( AZ 6197;AZ-6197 )
Catalog No. M13150 CAS No. 2023003-94-1
AZ6197 (AZ-6197) is a potent, selective, reversible inhibitor of ERK1/2 with IC50 of <0.3 nM (ERK2).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
100MG | Get Quote | Get Quote |
|
200MG | Get Quote | Get Quote |
|
500MG | Get Quote | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameAZ6197
-
NoteResearch use only, not for human use.
-
Brief DescriptionAZ6197 (AZ-6197) is a potent, selective, reversible inhibitor of ERK1/2 with IC50 of <0.3 nM (ERK2).
-
DescriptionAZ6197 (AZ-6197) is a potent, selective, reversible inhibitor of ERK1/2 with IC50 of <0.3 nM (ERK2), inhibits pERK/pRSK with IC50 of 12/62 nM in A375 cells, respectively; demonstrates in vivo antitumor efficacy.
-
SynonymsAZ 6197;AZ-6197
-
PathwayMAPK/ERK Signaling
-
TargetERK
-
RecptorERK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2023003-94-1
-
Formula Weight442.53
-
Molecular FormulaC24H26N8O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCC1CN2C=C(C=C2C(=O)N1CC3=CC=CC(=N3)C)C4=NC(=NC=C4C)NC5=CC=NN5C
-
Chemical Name(R)-3-Methyl-7-(5-methyl-2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)-2-((6-methylpyridin-2-yl)methyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ward RA, et al. J Med Chem. 2017 Apr 27;60(8):3438-3450.
2. Decaudin D, et al. Oncotarget. 2018 Apr 24;9(31):21674-21686.
2. Decaudin D, et al. Oncotarget. 2018 Apr 24;9(31):21674-21686.
molnova catalog
related products
-
MK-8353 hydrochlorid...
MK-8353 hydrochloride (SCH-900353) is a highly potent, orally bioavailable, dual-specificity ERK1/2 inhibitor with IC50 of 23.0/8.8 nM, respectively.
-
Muramyl dipeptide
Muramyl dipeptide is a synthetic immunoreactive peptide, consisting of N-acetyl muramic acid attached to a short amino acid chain of L-Ala-D-isoGln.
-
Byakangelicol
Byakangelicol may inhibit P-gp expressed at the BBB even under in vivo conditions.